

Supplementary Table 3. Results from the multivariate analyses of END, poor functional outcome at 3 months, and long-term all-cause mortality after the index stroke including the cardioembolic stroke subtype according to IASBD and IADBD

| | END* | | Poor functional outcome [†] | | All-cause mortality [‡] | |
|--|-------------------|-------|--------------------------------------|-------|----------------------------------|-------|
| | OR (95% CI) | p | OR (95% CI) | p | HR (95% CI) | p |
| IASBD | | | | | | |
| ≥5 mm Hg | 1.33 (0.99–2.04) | 0.054 | 1.12 (0.83–1.53) | 0.412 | 1.16 (0.64–1.96) | 0.498 |
| ≥10 mm Hg | 1.45 (1.01–3.12) | 0.032 | 1.96 (1.27–2.94) | 0.006 | 1.80 (1.13–3.21) | 0.031 |
| ≥15 mm Hg | 3.14 (1.04–7.81) | 0.018 | 2.03 (1.19–3.82) | 0.005 | 3.12 (1.52–6.03) | 0.015 |
| Per 1-mm Hg increase | 1.03 (1.00–1.08) | 0.002 | 1.03 (1.01–1.08) | 0.005 | 1.05 (1.01–1.09) | 0.007 |
| IADBD | | | | | | |
| ≥5 mm Hg | 1.84 (1.32–2.91) | 0.041 | 1.26 (0.92–1.72) | 0.152 | 1.62 (1.03–3.16) | 0.045 |
| ≥10 mm Hg | 3.03 (1.62–5.43) | 0.018 | 2.19 (1.14–2.84) | 0.005 | 3.12 (1.23–4.52) | 0.013 |
| ≥15 mm Hg | 4.31 (1.52–12.76) | 0.044 | 3.92 (1.30–6.53) | 0.043 | 6.21 (3.20–9.20) | 0.022 |
| Per 1-mm Hg increase | 1.08 (1.04–1.16) | 0.002 | 1.05 (1.01–1.10) | 0.013 | 1.11 (1.03–1.19) | 0.001 |
| Both IASBD ≥5 mm Hg and IADBD ≥5 mm Hg | 1.69 (1.24–4.08) | 0.023 | 1.22 (0.85–1.83) | 0.236 | 1.62 (0.93–2.79) | 0.085 |
| Both IASBD ≥10 mm Hg and IADBD ≥10 mm Hg | 2.25 (0.94–6.34) | 0.098 | 2.28 (1.35–5.36) | 0.035 | 7.63 (3.75–12.82) | 0.019 |

*Adjusted for sex, age, hypercholesterolemia, smoking, prior statin use, NIHSS score, stroke subtype, cerebral atherosclerosis, thrombolytic therapy, white blood cell count, and brachial-ankle pulse wave velocity; [†]Adjusted for sex, age, hypertension, metabolic syndrome, thrombolytic therapy, END, NIHSS score, stroke subtype, cerebral atherosclerosis, HGWMHs, and brachial-ankle pulse wave velocity; [‡]Adjusted for sex, age, hypertension, diabetes mellitus, metabolic syndrome, thrombolytic therapy, END, NIHSS score, stroke subtype, cerebral atherosclerosis, HGWMHs, and brachial-ankle pulse wave velocity.

END: early neurological deterioration, HGWMHs: high-grade white-matter hyperintensities, HR: hazard ratio, IADBD: interarm diastolic blood pressure difference, IASBD: interarm systolic blood pressure difference, NIHSS: National Institutes of Health Stroke Scale, OR: odds ratio.